Skip to content
Oncology Research Hub

Tampa, Florida

Cancer clinical trials in Tampa, FL

217 cancer studies are recruiting participants at sites in Tampa as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Tampa at a glance

  • 217 studies are recruiting at a site in Tampa.
  • By phase: Early Phase 1 (2), Phase 1 (33), Phase 1/2 (39), Phase 2 (56), Phase 2/3 (8), Phase 3 (50), No phase (9), Observational (20). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (125), university, hospital or other (80), government (12).
  • By research area: Lung Cancer (67), Breast Cancer (58), Lymphoma (44), Prostate Cancer (17), Melanoma (16), Pancreatic Cancer (15).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Tampa

Basic details from each study's public record (the 30 most recently updated of 217). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    H. Lee Moffitt Cancer Center and Research Institute
    Registry record
    NCT06324357 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Moffitt Cancer Center
    Registry record
    NCT03418961 · updated
  3. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT03606967 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Saint Joseph's Hospital/Children's Hospital-Tampa
    Registry record
    NCT06058377 · updated
  5. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06638307 · updated
  6. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07007559 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Lung cancer studies recruiting in Tampa

  1. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06216301 · updated
  2. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT06983743 · updated
  3. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07277413 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Moffit Cancer Center
    Registry record
    NCT07111520 · updated
  5. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Moffit Cancer Centre
    Registry record
    NCT07659782 · updated
  6. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Moffitt Cancer Center
    Registry record
    NCT04267848 · updated
  7. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study site
    Moffitt Cancer Center
    Registry record
    NCT04712877 · updated
  8. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    James A. Haley Veterans Affairs Hospital · Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus
    Registry record
    NCT06096844 · updated
  9. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT06498635 · updated
  10. Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

    • No phase
    • Ages 50 to 80
    • All sexes
    Sponsor
    bioAffinity Technologies Inc.
    Study site
    James A. Haley Veterans' Hospital
    Registry record
    NCT07168993 · updated
  11. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Moffitt Cancer Center ( Site 0021)
    Registry record
    NCT07221474 · updated
  12. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07458347 · updated
  13. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    University of South Florida, Department of Psychiatry and Behavioral Neuroscience
    Registry record
    NCT07002034 · updated
  14. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Tampa

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT04423211 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Melanoma studies recruiting in Tampa

  1. Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    H. Lee Moffitt Cancer Center and Research Institute
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07930182 · updated
  2. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    H. Lee Moffitt Cancer Center
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Tampa, FL on ClinicalTrials.gov.

Lymphoma studies recruiting in Tampa

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT06724237 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Tampa General Hospital ( Site 0134)
    Registry record
    NCT06717347 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Saint Joseph's Hospital/Children's Hospital-Tampa · Tampa General Hospital
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Saint Joseph's Hospital/Children's Hospital-Tampa · Tampa General Hospital
    Registry record
    NCT05675410 · updated
  5. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Moffitt Cancer Center · Moffitt Cancer Center - McKinley Campus · Moffitt Cancer Center-International Plaza
    Registry record
    NCT06337318 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Tampa, FL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Tampa

  1. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Moffitt Cancer Center
    Registry record
    NCT07644559 · updated
  2. Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Moffitt Cancer Center - McKinley Campus
    Registry record
    NCT06807437 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Tampa, FL on ClinicalTrials.gov.

Ask about studies near Tampa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call